Cargando…
Intractable Hepatic Encephalopathy with a Large Portosystemic Shunt Successfully Treated Using Shunt-preserving Disconnection of the Portal and Systemic Circulation
Hepatic encephalopathy (HE) is a significant symptom of decompensated liver cirrhosis. Occlusion of portosystemic shunts is used to treat refractory HE. Nevertheless, these treatments often cause adverse events, such as ascites and esophageal varices. We treated a 57-year-old man with refractory HE...
Autores principales: | Haraguchi, Masafumi, Hirai, Satoshi, Nakamura, Yutaka, Otsuka, Tetsuhiro, Ishimaru, Hideki, Sasaki, Ryu, Fukushima, Masanori, Miuma, Satoshi, Miyaaki, Hisamitsu, Nakao, Kazuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205523/ https://www.ncbi.nlm.nih.gov/pubmed/32009096 http://dx.doi.org/10.2169/internalmedicine.3955-19 |
Ejemplares similares
-
Shunt occlusion prior to lenvatinib administration prevents hepatic encephalopathy and hyperammonemia
por: Kuwahara, Ai, et al.
Publicado: (2020) -
Inferior Vena Cava Anomalies with Portal Vein System Continuation Presenting as Portal Hypertension with a Long-term Follow-up
por: Fukushima, Masanori, et al.
Publicado: (2020) -
Hepatic encephalopathy due to extrahepatic portosystemic shunt
por: Sazumi, Yosuke, et al.
Publicado: (2020) -
The impact of single-nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with direct-acting antiviral drugs for hepatitis C infection
por: Matsumoto, Kosuke, et al.
Publicado: (2022) -
Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)